Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Ethyl 6-chloro-4-(ethylamino)nicotinate is a chemical compound that belongs to the class of nicotinic acid esters. It is a derivative of nicotine and is often used in the pharmaceutical industry for its potential therapeutic properties. The chemical structure of ethyl 6-chloro-4-(ethylamino)nicotinate consists of an ethyl group, a chloro group, and an ethylamino group attached to a nicotinate moiety.
Used in Pharmaceutical Industry:
Ethyl 6-chloro-4-(ethylamino)nicotinate is used as a pharmaceutical compound for its potential therapeutic properties. Its unique chemical structure, which includes an ethyl group, a chloro group, and an ethylamino group attached to a nicotinate moiety, contributes to its potential use in various medical applications.
Used in Antiviral Applications:
Ethyl 6-chloro-4-(ethylamino)nicotinate is used as an antiviral agent, with its properties being investigated for their potential to combat viral infections. Its unique chemical structure may contribute to its antiviral activity, making it a promising candidate for further research and development in this area.
Used in Anti-inflammatory Applications:
Ethyl 6-chloro-4-(ethylamino)nicotinate is used as an anti-inflammatory agent, with its potential to reduce inflammation and alleviate related symptoms being investigated. Its chemical structure may play a role in its anti-inflammatory properties, making it a valuable compound for further study and potential use in treating inflammatory conditions.
Used in Analgesic Applications:
Ethyl 6-chloro-4-(ethylamino)nicotinate is used as an analgesic agent, with its potential to relieve pain being explored. Its unique chemical structure may contribute to its pain-relieving properties, making it a promising compound for the development of new pain management therapies.
Ethyl 6-chloro-4-(ethylamino)nicotinate is a subject of ongoing research, and its potential applications in various medical fields may hold promise for the development of new drugs. Its unique chemical structure and potential therapeutic properties make it an interesting compound for further investigation and potential use in the pharmaceutical industry.

959162-97-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 959162-97-1 Structure
  • Basic information

    1. Product Name: ethyl 6-chloro-4-(ethylamino)nicotinate
    2. Synonyms: ethyl 6-chloro-4-(ethylamino)nicotinate
    3. CAS NO:959162-97-1
    4. Molecular Formula: C10H13ClN2O2
    5. Molecular Weight: 228.67542
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 959162-97-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl 6-chloro-4-(ethylamino)nicotinate(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl 6-chloro-4-(ethylamino)nicotinate(959162-97-1)
    11. EPA Substance Registry System: ethyl 6-chloro-4-(ethylamino)nicotinate(959162-97-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 959162-97-1(Hazardous Substances Data)

959162-97-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 959162-97-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,1,6 and 2 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 959162-97:
(8*9)+(7*5)+(6*9)+(5*1)+(4*6)+(3*2)+(2*9)+(1*7)=221
221 % 10 = 1
So 959162-97-1 is a valid CAS Registry Number.

959162-97-1Relevant articles and documents

FGFR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

-

Paragraph 0077; 0080-0081, (2021/03/18)

A compound having a structure of formula (I) and a preparation method therefor, and a use of the compound serving as an FGFR inhibitor for treating tumors, cancers, myeloproliferative diseases, bone or chondrocyte disorders, and hypophosphatemia.

GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS

-

Page/Page column 38, (2021/05/15)

The present invention relates to certain gem-disubstituted heterocyclic compounds, which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutat

HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS

-

Page/Page column 49; 51, (2019/12/15)

The present invention relates to certain substituted heterocondensed pyridone analogues of formula (I) which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutat

Inhibitors of the fibroblast growth factor receptor

-

Page/Page column 44; 45, (2017/08/01)

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

-

Paragraph 0153; 0154; 0155, (2015/07/22)

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

MULTIPLE KINASE PATHWAY INHIBITORS

-

, (2014/04/17)

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

-

, (2013/06/27)

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

-

, (2014/01/08)

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS

-

, (2008/06/13)

Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 959162-97-1